Chromosomal aneuploidies are prognostic markers across a wide variety of tumor types, and recent literature suggests that pancreatic neuroendocrine tumors are no different. In this study 214 patients with grade 1, 2, or 3 pancreatic neuroendocrine tumors had their tissue examined for chromosomal copy number alterations using next-generation sequencing. Univariate and multivariate statistical analyses were performed with all-cause mortality and disease-specific mortality as the end comparators. As such, the cohort stratified into 3 different clinically relevant chromosomal subgroups: an indolent subgroup characterized by loss of chromosome 11 in relative isolation, an aggressive subgroup characterized by losses of chromosomes 1, 2, 3, 6, 10, 11, 16, and 22 and with no loss of chromosomes 4, 5, 7, 12, 14, 17, 19, and 20, and finally a heterogeneous third group with a subset of cases that behave even more aggressively than the aforementioned.

染色体非整倍体是多种肿瘤类型的预后标志物，最近的文献表明胰腺神经内分泌肿瘤也不例外。在这项研究中，214 名患有 1、2 或 3 级胰腺神经内分泌肿瘤的患者使用新一代测序技术检查了其组织中染色体拷贝数的变化。以全因死亡率和疾病特异性死亡率作为最终比较进行单变量和多变量统计分析。因此，该队列分为 3 个不同的临床相关染色体亚组：以相对隔离的 11 号染色体丢失为特征的惰性亚组，以 1、2、3、6、10、11、16 号染色体丢失为特征的侵袭性亚组，以及22 号染色体，并且没有丢失 4、5、7、12、14、17、19 和 20 号染色体，最后是异质第三组，其中一部分病例的行为比上述病例更具有攻击性。